Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced on September 17 that it completed its acquisition of Marea Therapeutics and signed a definitive agreement for a concurrent private placement expected to raise approximately $225 million gross. Financing completion was expected on September 18, subject to customary closing conditions.
Following both transactions, legacy equity holders of Lisata Therapeutics, Inc. would retain approximately 2.39% ownership on the stated fully diluted, as-converted basis. That calculation uses the treasury stock method and excludes beneficial ownership limits. Existing investors are receiving exposure to a substantially different pipeline through a much smaller proportional stake.
Bull Case
Lisata Therapeutics, Inc. projects that the financing will support operations into 2028. Management expects fourth-quarter 2027 data from the MAR001 Phase 2b study in severe hypertriglyceridemia, or very high triglyceride levels, and the MAR002 Phase 2 program in acromegaly, a disorder involving excess growth hormone. The projected funding period extends beyond those planned results.
For Lisata Therapeutics, Inc., that alignment between funding and clinical milestones is the strongest argument for the transaction. Completing patient studies could provide evidence to assess whether the acquired medicines warrant larger trials and further investment. Having resources available through expected results could also reduce pressure to seek capital before the programs produce meaningful data.
Two programs offer separate opportunities to establish clinical value. Successful results could support development partnerships or improve the terms of future financing. Those possibilities make the acquired assets and available capital central to assessing what the retained ownership might ultimately be worth.
Bear Case
The dilution at Lisata Therapeutics, Inc. is substantial. On the disclosed basis, former Marea equity holders would own approximately 59.54%, while private-placement investors would own approximately 38.07%. Legacy investors therefore depend on the combined business becoming valuable enough to make their small remaining interest economically meaningful.
The ownership percentages alone cannot settle that valuation question. Investors need to weigh the acquired assets, financing proceeds and development obligations against the value of continuing with the previous business.
Lisata Therapeutics, Inc. also needs shareholder approval to convert the Series C non-voting preferred stock into common shares. The acquisition and private placement themselves do not require that approval.
The preferred-stock terms provide that, after six months from initial issuance, certain failures to deliver shares following a valid conversion notice can require cash settlement at the holder’s request. Payment is based on contractually defined fair value and subject to exceptions and legally available funds. Such payments could divert money from trials and shorten the projected funding period.
Clinical risk persists throughout the funding period. The planned studies must establish convincing efficacy and safety, and delays could increase spending before decisive results arrive. Positive Phase 2 findings would still leave further development and regulatory work ahead. The $225 million is a gross financing amount, with placement-agent and other offering expenses reducing the cash available for operations.
Hedge Fund Sentiment
The filings available so far reflect positions held before Lisata Therapeutics, Inc. reported its Marea acquisition and concurrent private placement. Insider Monkey’s database showed 3 hedge funds holding Lisata Therapeutics, Inc. at the end of 2Q2026, down from 4 funds three months earlier.
Conclusion
Lisata Therapeutics, Inc. is undertaking a fundamental business reset. Funding through planned clinical results could give the acquired pipeline a credible development path, but legacy investors surrender substantial proportional ownership. Financing completion, conversion-related cash obligations, and the quality of the 2027 trial results will help determine whether that trade creates value.
READ NEXT: Korn Ferry (KFY) Grew Contracted Fees 14%. Can AMS Add Growth Without Squeezing Margins? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center